Skip to Main Content

Paper Details

LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
Cancer Lett
15
2020
Author NameAffiliation
Enrique de AlavaCarlos III Institute of Health (ISCIII), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocio/CSIC/Universidad de Sevilla
Oscar M TiradoBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Carlos III Institute of Health (ISCIII), Spain Institut Catala D'Oncologia (ICO)
  • 1 - 2

Datasets

Release 1.2